Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER
Barclays Downgrades Amgen to Underweight, Upgrades Gilead
© Reuters.
By Senad Karaahmetovic
Barclays analysts downgraded shares of Amgen (NASDAQ:AMGN) to Underweight from Equal Weight with a price target of $234 per share.
With Amgen shares up over 20% in October, the analysts see risk-reward tilted to the downside, given the high expectations into the AMG133 (early-stage obesity asset) update, which should occur during the AHA analyst call on November 7.
The event is seen as a "higher impact catalyst," given that AMG133 "faces high hurdles on efficacy and tolerability (with limited data shared to date) and Amgen faces questions on speed of development path and ability to compete with entrenched competition."
As a result, the analysts see Amgen shares under pressure bearing in mind the recent gains.
Conversely, the analysts upgraded Gilead Sciences (NASDAQ:GILD) to Equal Weight with a price target of $76 per share, up from $60.
"Given the lack of a relevant catalyzing event on the horizon with meaningful downside, coupled with the company's solid execution commercially, it was clear that GILD no longer warranted our UW rating - a position we should have moved off of earlier," the analysts wrote in a separate note.
Amgen and Gilead shares are down 2.3% and 0.7%, respectively.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.